Jun 11, 2020
Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout
Apr 30, 2020
China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Apr 22, 2020
Invitation - Presentation of Sobi's Q1 2020 Results
Apr 22, 2020
Sobi(TM) Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia
Apr 20, 2020
Sobi Offers Advance Voting at the 2020 Annual General Meeting
Apr 13, 2020
Sobi Sees Strong Revenue and EBITA Growth in the First Quarter 2020
Apr 07, 2020
Sobi(TM) Publishes 2019 Annual and Sustainability Report
Feb 13, 2020
Sobi Publishes Report for the Fourth Quarter and Full-year 2019
Feb 04, 2020
Invitation - Presentation of Sobi's Q4/FY 2019 Results
Jan 13, 2020
Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
Dec 21, 2019
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia
Dec 09, 2019
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates
Dec 09, 2019
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Nov 10, 2019
Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals
Oct 31, 2019
Sobi Publishes Report for Third Quarter 2019
Oct 23, 2019
Invitation - Presentation of Sobi's Q3 2019 Results
Aug 22, 2019
Sobi has Entered Into Agreement to Sell Priority Review Voucher
Jul 17, 2019
Sobi Publishes Report for Second Quarter 2019
Jun 12, 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Jun 12, 2019
Sobi Acquires Emapalumab and Related Assets